We are live on ! Find out more
GNCA

Genocea Biosciences, Inc.
GNCA

Delisted

GNCA was delisted on the 2nd of June, 2022.

Back to rankings

56 hedge funds and large institutions have $9.81M invested in Genocea Biosciences, Inc. in 2017 Q4 according to their latest regulatory filings, with 9 funds opening new positions, 15 increasing their positions, 16 reducing their positions, and 15 closing their positions.

New
Increased
Maintained
Reduced
Closed

0% more funds holding in top 10

Funds holding in top 10: 1 → 1 (0)

6% less repeat investments, than reductions

Existing positions increased: 15 | Existing positions reduced: 16

10% less funds holding

Funds holding: 62 → 56 (-6)

33% less capital invested

Capital invested by funds: $14.6M → $9.81M (-$4.75M)

40% less first-time investments, than exits

New positions opened: 9 | Existing positions closed: 15

Holders
56
Holders Change
-6
Holders Change %
-9.68%
% of All Funds
1.27%
Holding in Top 10
1
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.02%
New
9
Increased
15
Reduced
16
Closed
15
Calls
$17K
Puts
–
Net Calls
+$17K
Net Calls Change
+$258K

Top Buyers

Rank Fund Capital Flow
1
ARTA
A.R.T. Advisors
New York
+$216K
2
Millennium Management
Millennium Management
New York
+$157K
3
Balyasny Asset Management
Balyasny Asset Management
Illinois
+$139K
4
Deutsche Bank
Deutsche Bank
Germany
+$51.1K
5
TCIM
TIAA CREF Investment Management
New York
+$31K

Top Sellers

Rank Fund Capital Flow
1
Axa
Axa
France
-$844K
2
SFM
Sphera Funds Management
Israel
-$715K
3
Fidelity Investments
Fidelity Investments
Massachusetts
-$529K
4
BCM
Bridgeway Capital Management
Texas
-$220K
5
Vanguard Group
Vanguard Group
Pennsylvania
-$154K
Name Holding Trade Value Shares
Change 		Change in
Stake
PVMCV
1
Polaris Venture Management Co V
Massachusetts
$2.28M – – –
BlackRock
2
BlackRock
New York
$1.71M +$14.9K +1,477 +0.8%
Vanguard Group
3
Vanguard Group
Pennsylvania
$958K -$154K -15,350 -13%
NC
4
Northpointe Capital
Michigan
$912K -$46.4K -4,618 -4%
Fidelity Investments
5
Fidelity Investments
Massachusetts
$560K -$529K -52,623 -47%
State Street
6
State Street
Massachusetts
$430K -$2.69K -267 -0.6%
Northern Trust
7
Northern Trust
Illinois
$348K -$7.24K -720 -2%
AA
8
AlphaMark Advisors
Kentucky
$339K -$16.3K -1,619 -4%
Balyasny Asset Management
9
Balyasny Asset Management
Illinois
$254K +$139K +13,788 +102%
VF
10
Virtu Financial
New York
$244K +$8.98K +893 +4%
Geode Capital Management
11
Geode Capital Management
Massachusetts
$213K -$16.8K -1,673 -7%
ARTA
12
A.R.T. Advisors
New York
$199K +$216K +21,517 New
Millennium Management
13
Millennium Management
New York
$145K +$157K +15,650 New
QOP
14
Quinn Opportunity Partners
Virginia
$131K -$12.6K -1,250 -8%
TCIM
15
TIAA CREF Investment Management
New York
$121K +$31K +3,086 +31%
Bank of New York Mellon
16
Bank of New York Mellon
New York
$105K +$5.79K +576 +5%
Deutsche Bank
17
Deutsche Bank
Germany
$79K +$51.1K +5,078 +142%
GCP
18
GSA Capital Partners
United Kingdom
$74K +$18.2K +1,812 +29%
California Public Employees Retirement System
19
California Public Employees Retirement System
California
$70K – – –
Morgan Stanley
20
Morgan Stanley
New York
$68K +$15.2K +1,516 +26%
TA
21
Teachers Advisors
New York
$60K – – –
California State Teachers Retirement System (CalSTRS)
22
California State Teachers Retirement System (CalSTRS)
California
$55K – – –
BC
23
Birchview Capital
Vermont
$45K – – –
MA
24
MYDA Advisors
New York
$39K +$42.1K +4,188 New
New York State Common Retirement Fund
25
New York State Common Retirement Fund
New York
$35K – – –
1
2 3

GNCA Hedge Fund Activity: Q4 2017 in Review

56 of the 4,409 institutional investors tracked by Wall St. Rank reported a position in Genocea Biosciences, Inc. (GNCA) for Q4 2017, worth a combined $9.81M — down 33% from $14.6M a quarter earlier.

Sellers outnumbered buyers: 15 funds closed out of GNCA and 9 opened new positions — a net loss of 6 holders — while 16 trimmed existing stakes and 15 added.

The largest buyer was A.R.T. Advisors, opening a new position worth an estimated $216K. The largest seller was Axa, exiting entirely with an estimated $844K sold.

  • 56 institutional investors held Genocea Biosciences, Inc. (GNCA) as of Q4 2017, down from 62 in Q3 2017.
  • Funds reported $9.81M of Genocea Biosciences, Inc. stock for Q4 2017, down 33% quarter-over-quarter.
  • 9 funds opened new Genocea Biosciences, Inc. positions in Q4 2017 and 15 closed out, a net change of -6 holders.
  • The largest Genocea Biosciences, Inc. buyer in Q4 2017 was A.R.T. Advisors, an estimated $216K added.
  • The largest Genocea Biosciences, Inc. seller in Q4 2017 was Axa, an estimated $844K sold.

Based on aggregated 13F filings for Q4 2017.